CXCL16 and cancer: Moreover, blocking of CXCR4, the chemokine receptor for CXCL12, and neutralization of CXCL16, the ligand for CXCR6 in patient-specific cancer cells significantly prevented the migration of cancer cells to the tumor microenvironment (TME).